Sarabjit Kour Nangra of Angel Broking shares her outlook on the road ahead for Infosys. Money Control, 2 weeks ago
Infosys: How analysts read Q1 numbers - MyIris, 2 weeks ago
Infosys Q1 beats forecast; recommends 'Buy': Angel Broking - MyIris, 2 weeks ago
2 images for "sarabjit kour nangra"
Sarabjit Kour Nangra VP Research- Pharma Angel Broking W The Nexium Generic is a bigger opportunity for Ranbaxy than Valcyte generic, she says in an interview with CNBC-TV18's Ekta Batra. Given the Sun-Ranbaxy merger, Nangra sees an upside ...Moneycontrol.com, 4 weeks ago Launch of generic diovan key opportunities for Ranbaxy: Angel Broking MyIris, 4 weeks ago
Wipro, India's third-biggest IT services exporter, reported 29 per cent growth in June quarter profit at Rs 2,118 crore compared with Rs 1,631 crore posted for the corresponding quarter last year. Total revenue stood at Rs 11,135 crore against Rs ...Financial Chronicle, 1 day ago UPDATE 2-India's Wipro sees strong sales growth, eyes Europe deals Reuters, 1 day ago Wipro sees strong sales growth, eyes Europe deals The Week, 23 hours ago India's Wipro sees strong sales growth, eyes Europe deals Sharenet, 1 day ago
Ipca Laboratories said it has voluntarily stopped shipments to the US from its bulk drug manufacturing facility at Ratlam, Madhya Pradesh, after the Food and Drug Administration The letter outlined a half a dozen violations of standard production ...DNA India, 1 day ago After FDA concerns, Ipca halts drug shipment to US Financial Chronicle, 1 day ago Angel Broking maintains 'Buy' on IPCA Lab MyIris, 1 day ago Ipca stops US shipments of products from Ratlam facility The Hindu, 1 day ago
Mumbai, July 23: Tata Consultancy Services (TCS), India's largest software services player, today became the first domestic company to surpass Rs 5 lakh crore in market capitalisation. On a day when the key indices hit fresh records, the TCS scrip ...Calcutta Telegraph, 2 days ago
Indoco Remedies has received a nod from the USFDA for two of its facilities in Goa. The US health regulator has approved the sterile facility (plant-II) and solid dosage facility (plant -III) located at Verna. Commenting on the same, Sarabjit Kour Nangra , VP ...Myiris, 3 days ago
India capped prices of 50 diabetes and heart treatments last week, with limits possible for other medications too. Photo: Bloomberg Mumbai: India's widening of price controls to drugs with revenues of about $915 million adds pressure on the local ...Livemint.com, 6 days ago Price Caps on $915 Million of Drugs Hurt Sanofi: Corporate India BusinessWeek, 1 week ago
Shares of TCS today ended nearly 3 per cent higher after the country's largest software exporter posted better-than-expected earnings in the June quarter. Boosted by the smart earnings, TCS's shares settled 2.58 per cent higher at Rs 2,442.65 on ...Business Standard India, 1 week ago TCS shares surge over 4 p.c on positive results The Hindu, 1 week ago
The National Pharmaceutical Pricing Authority (NPPA) has decided to fix the prices of 50 anti-diabetic and cardiac medicines. While the move will help consumers, it will erode the margins of pharmaceutical companies. The reduction will range from ...Hindu Business Line, 1 week ago Indian drug regulator puts price ceiling on 108 diabetes, cardiac formulations VC Circle, 1 week ago Drug price reduction to impact Sanofi, Zydus Cadila, Ranbaxy most: Experts MyIris, 1 week ago More drugs under NPPA coverage: Angel Broking MyIris, 1 week ago
The pharmaceutical industry, still coming to terms with the Drug Price Control Order (DPCO), 2013, which controls the prices of 652 drugs coming under the National List of Essential Medicines (NLEM), now has to deal with 108 more formulations, which ...The Hindu, 1 week ago
on your WebpageAdd Widget >Get your members hooked!